Skip to main content

Table 2 Demographic and clinical characteristics by treatment received among patients with gBRCA1/2mut HER2− ABC

From: Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

 

Unadjusted

IPWRA-Adjusted

PARPi Monotherapy (n = 38)

Chemotherapya

(n = 58)

P Values

PARPi Monotherapy (n = 38)

Chemotherapya

(n = 58)

Mean age at therapy initiation, years

50.7

51.3

0.829

50.2

50.5

Female sex, %

100

100

1.000

100

100

White race, %

86.8

93.1

0.476

91.9

85.8

Premenopausal, %

44.7

41.4

0.834

43.7

43.7

HR+/HER2− status, %

31.6

36.2

0.667

34.5

38.4

Currently known to be working full/part time, %

28.9

24.1

0.640

30.4

25.2

Charlson Comorbidities Index, mean

6.2

7.5

0.017

7.1

7.1

Baseline toxicities,b %

 Constitutional

47.4

36.2

0.296

29.6

33.9

 Pulmonary

31.6

19.0

0.221

20.1

19.3

 Gastrointestinal

26.3

15.5

0.204

14.7

15.4

 Dermatologic

36.8

8.6

0.001

19.2

15.7

 Neurologic

18.4

1.7

0.006

8.5

6.1

 Psychological

18.4

5.2

0.047

9.9

9.4

 Physical

63.2

29.3

0.002

34.4

38.8

 Pain

34.2

20.7

0.159

23.4

23.8

ECOG performance status at treatment initiation, mean

0.7

0.8

0.460

0.75

0.80

Stage IV at current treatment initiation, %

65.8

89.7

0.008

82.3

83.0

Line of current treatment, mean

1.9

1.4

0.002

1.6

1.6

  1. ABC Advanced breast cancer, gBRCA1/2mut Germline breast cancer susceptibility gene 1 or 2 mutation, ECOG Eastern Cooperative Oncology Group, HER2– Human epidermal growth factor receptor 2–negative, HR+ Hormone receptor–positive, IPWRA Inverse-probability–weighted regression adjustment, PARPi Poly (ADP-ribose) polymerase inhibitors
  2. Student’s t test
  3. Fisher’s exact test
  4. aIncludes platinum- and non–platinum-based regimens
  5. bInitial toxicities patients experienced that were retrospectively reported by physicians
  6. Bold P-values represent those that are statistically significant (p < 0.05)